IgA Nephropathy
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About IgA Nephropathy

What is the definition of IgA Nephropathy?
IgA nephropathy is a kidney disorder that occurs when IgA (immunoglobulin A), a protein that helps the body fight infections, settles in the kidneys. In the early stages, IgA nephropathy has no symptoms. The first sign of this condition may be blood in the urine. End-stage kidney disease may develop. In most instances, the cause of this condition is unknown; however, certain disorders have been linked with IgA nephropathy, such as cirrhosis of the liver, celiac disease, and HIV infection. Although IgA nephropathy usually occurs in a family with no other affected members, several cases of familial IgA nephropathy have been reported. Familial IgA nephropathy is suspected to run through families in an autosomal dominant manner and is linked to genetic material on the long arm of chromosome 6 (6q22-23).
What are the alternative names for IgA Nephropathy?
  • IgA nephropathy
  • Berger disease
  • Berger's disease
  • Glomerulonephritis, IGA
  • IGAN
  • Nephritis, IGA type
Who are the top IgA Nephropathy Local Doctors?
Elite in IgA Nephropathy
Elite in IgA Nephropathy

Georgia Nephrology

595 Hurricane Shoals Road Northwest, 
Lawrenceville, GA 
Languages Spoken:
English
Accepting New Patients

James Tumlin is a Nephrologist in Lawrenceville, Georgia. Dr. Tumlin is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. His top areas of expertise are IgA Nephropathy, Lupus Nephritis, Glomerulonephritis, Focal Segmental Glomerulosclerosis, and Kidney Transplant. Dr. Tumlin is currently accepting new patients.

Ali G. Gharavi
Elite in IgA Nephropathy
Elite in IgA Nephropathy

CUIMC/Russ Berrie Medical Science Pavilion

1150 St. Nicholas Avenue, 
New York, NY 
Languages Spoken:
English

"Dr. Ali Gharavi is a kidney specialist with expertise in human genetics. He is the Harold Ames Hatch (II) Professor of Medicine and currently serves as Chair of the Department of Medicine at Columbia University Vagelos College of Physicians and Surgeons, and Physician-in-Chief, NewYork-Presbyterian Hospital/Columbia. He previously served as the Chief of the Division of Nephrology at NewYork-Presbyterian/Columbia University Irving Medical Center.The principal investigator on multiple research projects funded by the National Institutes of Health (NIH), Dr. Gharavi has specific interests in the genetics of kidney diseases, including IgA nephropathy and congenital abnormalities of the kidney and urinary tract. His research has identified genes and risk loci for many kidney diseases and has demonstrated the utility of sequencing for the diagnosis and management of patients with kidney disorders.""Owing to the recent progress in genomic technologies, we now have the opportunity to make a precise genetic diagnosis for many patients and individualize care based on the specific molecular mechanism of disease. My objective is to therefore bring personalized genomic medicine from the laboratory into patient care,"" says Dr. Gharavi. As Department Chair, he aims to enhance access to genomic medicine for patients and reduce disparities for underserved populations.After receiving his medical degree from George Washington University, Dr. Gharavi completed his Internal medicine residency at Mount Sinai Medical Center and fellowships in hypertension and nephrology, also at Mount Sinai. He then completed a postdoctoral fellowship in human genetics at Yale University School of Medicine. He previously held academic appointments at Yale University School of Medicine and Mount Sinai School of Medicine and hospital appointments at Mount Sinai Hospital. Dr. Gharavi is the author of over 200 peer-reviewed publications and has led national and International committees related to genetic testing and research for kidney disorders. He was a recipient of the Judson Daland Prize for Outstanding Clinical Investigation from the American Philosophical Society, the National Kidney Foundation Clinical Scientist Award, and Homer Smith Award from the American Society of Nephrology. He was elected to the American Society of Clinical Investigation and the American Association of Physicians.". Dr. Gharavi is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. His top areas of expertise are IgA Nephropathy, Glomerulonephritis, Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, and Kidney Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in IgA Nephropathy
Elite in IgA Nephropathy

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
Languages Spoken:
English
Offers Telehealth

Richard Lafayette is a Nephrologist in Stanford, California. Dr. Lafayette is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. His top areas of expertise are IgA Nephropathy, Glomerulonephritis, Focal Segmental Glomerulosclerosis, Chronic Kidney Disease, and Kidney Transplant.

What are the latest IgA Nephropathy Clinical Trials?
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

Summary: In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effect felzartamab has on proteinuria. The main question that researchers want to answer is: • How much d...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants With Primary IgA Nephropathy in Combination With Stable Background Therapy

Summary: Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein leve...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center